future glp-1 drugs the of glp 1 What's next for innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 Users: Trends on Long-Term

Furthermore, some individuals taking these medications might experience changes in their eating habits due to decreased appetite, sometimes leading to nutritional deficiencies if a balanced diet is not maintained

This combination is recommended for individuals with a BMI over 30 (obesity), or individuals with both a BMI of 27 (overweight) or greater with a weight related health problem such as hypertension or diabetes

GLP-1 receptor agonists are drugs that mimic the action of our naturally occurring hormone, Glucagon-like peptide-1 (GLP-1)

Gastrointestinal symptoms: nausea (20%), diarrhea (15%), vomiting (11%), constipation (6%), dyspepsia (6%), abdominal pain (5%), eructation (4%), gastroesophageal reflux disease (3%), abdominal distension (2%) and flatulence (2%)

Key takeaways The Medicare GLP-1 Bridge Program is live

GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD